Compare Adaptive Biotechnologies Corp (ADPT) vs Dicks Sporting Goods Inc (DKS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Dicks Sporting Goods Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Dicks Sporting Goods Inc trades at $216.14 (market cap $19.97B). The key difference: Dicks Sporting Goods Inc is far larger — about 6× Adaptive Biotechnologies Corp's market cap, and Dicks Sporting Goods Inc pays a 2.24% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | DKS | |
|---|---|---|
Market Cap | $3.33B | $19.97B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $239.17 |
52-Week Low | $10.24 | $187.78 |
Enterprise Value | $3.19B | $26.76B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Dick's Sporting Goods (DKS) trades at $229.02, down 3.03% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong fundamentals with consistent earnings beats, a P/E of 22.3, and a net income margin of 4.71%. Recent developments include the launch of ScoreCard+ loyalty program and partnerships with Lids, enhancing growth prospects amid positive analyst sentiment.
The outlook for DKS is positive, supported by robust earnings performance and strategic initiatives. Risks include potential fiduciary concerns highlighted in recent legal investigations and competitive pressures. With a consensus price target of $261, representing a 14% upside, the stock presents a compelling opportunity, though investors should monitor execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →
